Literature DB >> 28935991

Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis.

J-C Hernández-Boluda1, A Pereira2, J-G Correa3, A Alvarez-Larrán4, F Ferrer-Marín5, J-M Raya6, J Martínez-López7, M Pérez-Encinas8, N Estrada9, P Velez10, M-L Fox11, V García-Gutiérrez12, A Payer13, A Kerguelen14, B Cuevas15, M-A Durán16, M-J Ramírez17, M-T Gómez-Casares18, M-I Mata-Vázquez19, E Mora20, C Martínez-Valverde21, M Gómez1, F Cervantes3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28935991     DOI： 10.1038/leu.2017.297

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Explained variation in survival analysis.

Authors:  M Schemper; J Stare
Journal:  Stat Med       Date:  1996-10-15       Impact factor: 2.373

Review 2.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors:  N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

3.  The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

Authors:  Juan-Carlos Hernández-Boluda; Arturo Pereira; Montse Gómez; Concepción Boqué; Francisca Ferrer-Marín; José-María Raya; Valentín García-Gutiérrez; Ana Kerguelen; Blanca Xicoy; Pere Barba; Jesús Martínez; Elisa Luño; Alberto Alvarez-Larrán; Joaquín Martínez-López; Elisa Arbelo; Carles Besses
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

4.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

5.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Authors:  Naseema Gangat; Domenica Caramazza; Rakhee Vaidya; Geeta George; Kebede Begna; Susan Schwager; Daniel Van Dyke; Curtis Hanson; Wenting Wu; Animesh Pardanani; Francisco Cervantes; Francesco Passamonti; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

6.  Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

Authors:  Lucia Masarova; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Kate J Newberry; Taghi Manshouri; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2017-06-02       Impact factor: 3.156

7.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

8.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

9.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Authors:  G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi
Journal:  Leukemia       Date:  2007-08-30       Impact factor: 11.528

10.  How I treat myelofibrosis.

Authors:  Francisco Cervantes
Journal:  Blood       Date:  2014-09-16       Impact factor: 22.113
View more
  5 in total

Review 1.  Mutational profiling in myelofibrosis: implications for management.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2019-10-19       Impact factor: 2.490

2.  Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis.

Authors:  María García-Fortes; Juan C Hernández-Boluda; Alberto Álvarez-Larrán; José M Raya; Anna Angona; Natalia Estrada; Laura Fox; Beatriz Cuevas; María C García-Hernández; María Teresa Gómez-Casares; Francisca Ferrer-Marín; Silvana Saavedra; Francisco Cervantes; Regina García-Delgado
Journal:  Cancers (Basel)       Date:  2022-05-09       Impact factor: 6.575

Review 3.  Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Authors:  Francesco Passamonti; Barbara Mora; Daniela Barraco; Margherita Maffioli
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 4.  The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review.

Authors:  Mario Tiribelli; Francesca Palandri; Emanuela Sant'Antonio; Massimo Breccia; Massimiliano Bonifacio
Journal:  Bone Marrow Transplant       Date:  2019-09-18       Impact factor: 5.483

Review 5.  Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.

Authors:  Lining Zhang; Fan Yang; Sizhou Feng
Journal:  Ther Adv Hematol       Date:  2020-02-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.